New launch momentum: Sun Pharma’s Ilumya expansion targets plaque psoriasis growth

Sun Pharma is pushing deeper into immunology with its biologic Ilumya for moderate-to-severe plaque psoriasis, adding new market approvals and real-world data as it sharpens its specialty medicine focus.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 4:18 AM ET. Details in the imprint.

With immunology seen as one of its key growth engines, Sun Pharmaceutical Industries is leaning harder on its biologic Ilumya (tildrakizumab) for adults with moderate-to-severe plaque psoriasis, highlighting fresh launch momentum as the drug rolls out across additional markets and indications. The interleukin-23p19 (IL-23p19) inhibitor is already approved in the US, Europe and several other geographies for patients who are candidates for systemic therapy or phototherapy, and Sun Pharma continues to position it as a long-term maintenance option built around a relatively infrequent dosing schedule. The official US product information details its use in adults with moderate-to-severe plaque psoriasis who are eligible for systemic therapy or phototherapy.

What Ilumya does and how Sun Pharma is expanding it

Ilumya is a humanized monoclonal antibody that selectively binds to the p19 subunit of interleukin-23, a cytokine implicated in the pathogenesis of plaque psoriasis, thereby inhibiting IL-23 mediated signaling and reducing inflammation in the skin. In clinical studies, a majority of treated patients achieved at least 75 percent improvement on the Psoriasis Area and Severity Index (PASI 75), with a substantial proportion reaching PASI 90 or near-clear skin after several months of therapy, and many maintained response with ongoing injections every 12 weeks after the initial loading doses. Sun Pharma emphasizes that the fixed 100 mg dose and quarterly maintenance schedule are designed to simplify adherence compared with some biologics that require more frequent injections, which is a meaningful differentiator for working-age patients managing a chronic disease.

Sun Pharma licensed tildrakizumab from Merck & Co. and has built Ilumya into a central piece of its specialty pipeline, particularly in the US and key emerging markets where biologic penetration in dermatology is still growing from a lower base. The company has reported rising prescription volumes in dermatology and immunology, supported not only by psoriasis indications but also by ongoing development in psoriatic arthritis and other potential autoimmune settings where IL-23 inhibition is mechanistically relevant. In its recent investor updates, Sun Pharma has highlighted specialty medicines as a fast-growing revenue pillar, with dermatology-focused brands such as Ilumya contributing a disproportionate share of growth compared with the broader generics portfolio. Company presentations point to expanding Ilumya sales alongside other key specialty products.

The commercial strategy around Ilumya combines traditional dermatologist detailing with patient-support programs designed to lower access barriers in markets where biologics can be expensive relative to household income. In the US, the list price aligns with other advanced psoriasis biologics, but net pricing is shaped by rebates to commercial insurers and pharmacy benefit managers as well as copay assistance programs targeting eligible patients. Outside the US, Sun Pharma often works with public payers and hospital systems to secure formulary placement, while in India and other cost-sensitive markets it may need to calibrate pricing and distribution to build scale over time; in those regions, branded generics still dominate psoriasis treatment, but biologic use is slowly picking up as awareness and reimbursement improve. For clinicians, the safety profile of Ilumya - including a generally low rate of serious infections in trials - and the convenience of 12-week dosing can be critical considerations when choosing among multiple IL-23 and IL-17 competitors.

To support prescribers, Sun Pharma and its partners have been publishing longer-term real-world data and extension-study results, which suggest that a significant portion of patients who respond to Ilumya maintain high levels of skin clearance for several years without new safety signals. In addition to regulatory-required pharmacovigilance, the company has sponsored observational registries in dermatology practices to track adherence and outcomes in routine clinical settings, where patient comorbidities such as obesity, metabolic syndrome and psoriatic arthritis frequently coexist. These datasets help Sun Pharma argue that consistent IL-23 blockade with Ilumya can reduce disease burden and potentially improve quality of life measures such as Dermatology Life Quality Index scores, supporting its positioning against established players from larger multinational competitors.

From a portfolio perspective, Ilumya sits at the intersection of Sun Pharma's specialty medicine ambitions and its traditional strength in dermatology and rheumatology prescriptions, making the product strategically important despite competition from other biologics and newer small molecules. The company has flagged specialty products - led by Ilumya, along with ophthalmology and neurology brands - as a rising share of revenue, helping diversify away from generic price pressure in the US. According to market data from India, shares of Sun Pharmaceutical Industries (ISIN INE044A01036) traded on the National Stock Exchange of India at around ?1,806 on 06/16/2026, underscoring investor focus on the group's ability to grow its higher-margin specialty franchise over time. Recent NSE price information shows Sun Pharma changing hands in this range.

Ilumya quick profile: the key figures

• Product: Ilumya (tildrakizumab)
• Manufacturer: Sun Pharmaceutical Industries Ltd
• Category: New Release/Launch - specialty biologic for plaque psoriasis
• Launch date: US approval in 2018 for moderate-to-severe plaque psoriasis
• MSRP / Price: Biologic-level pricing, with net cost varying by payer and market; list prices broadly comparable to other advanced psoriasis biologics in the US
• Availability: Prescription-only, marketed in the US, Europe and multiple other countries via Sun Pharma and partners
• Target audience: Adults with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy
• Key differentiator / USP: IL-23p19 inhibition with fixed 100 mg dosing and 12-week maintenance interval after loading

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.